Combined Exposure Therapy and D-Cycloserine vs. Placebo for Posttraumatic Stress Disorder

This study provides a 12-14 week treatment for posttraumatic stress disorder related to the World Trade Center Attacks of September 11, 2001. Every patient will receive weekly individual therapy consisting of cognitive-behavioral treatment, including exposure therapy. In this treatment study, exposure will be enhanced by virtual reality and each patient will be randomly assigned to receive either D-Cycloserine or a placebo pill that is taken only on the day of the treatment when the exposure will be done for a total of 10-12 times. D-Cycloserine is a broad spectrum antibiotic that recently has been implicated as a cognitive enhancer which may speed up the learning process that occurs during exposure and/or make the gains more lasting.

Organization: 
New York Presbyterian Hospital/Weill Cornell Medical College
Principal Investigator: 
JoAnn Difede, PhD
Eligibility Criteria: 

Participants must be English-speaking adults with PTSD who witnessed the WTC attacks from nearby or farther and who are medically stable. Patients cannot participate if they have a serious comorbid mental illness, active suicidal or homicidal ideation, use a pacemaker, are pregnant or lactating, have a history of severe renal disease, seizures, or allergy to DCS, or are currently taking anticoagulants, ethionamide, or isoniazid.

Contact: 
Brittany Mello at The Program for Anxiety and Traumatic Stress Studies, 212-821-0783
Location: 
New York, NY
State: 
New York

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.